Sunshine Biopharma (SBFM) Finished Goods (2019 - 2020)

Sunshine Biopharma (SBFM) reported Finished Goods of $23771.0 for Q4 2020, up 49.41% on a YoY basis from $15910.0 in Q1 2020, and up 49.41% quarter-over-quarter from $15910.0 in Q4 2019.

Sunshine Biopharma (SBFM) Finished Goods (2019 - 2020) Analysis & Trends

Sunshine Biopharma has reported Finished Goods for 2 years, with the latest figure at $23771.0 in Q4 2020.

  • For the quarter ending Q4 2020, Finished Goods rose 49.41% year-over-year to $23771.0; the trailing twelve-month figure through Dec 2020 stood at $23771.0 (up 49.41% YoY), and the FY2020 full-year result was $23771.0, up 49.41% from the prior year.
  • Finished Goods for Q4 2020 stood at $23771.0, up from $15910.0 in the prior quarter.
  • The five-year high for Finished Goods was $23771.0 in Q4 2020, with the low at $15910.0 in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Sunshine Biopharma 10.94 Mn 4.03 Mn 2.18 Mn

Historic Data

Download Data
DateValue
Dec 31, 2020 23,771.00
Dec 31, 2019 15,910.00